[CD200 protein, bad prognostic in patients with multiple myeloma].


BACKGROUND Multiple myeloma (MM) is a monoclonal gammopathy characterized by abnormal proliferation of malignant plasma cells. The median overall survival rate has changed from 2-3 to 5-6 or more years with the introduction of novel agents. Recently CD200 protein has been described as an immunosuppressive protein that confers a poor prognostic factor in… (More)


Cite this paper

@article{VelaOjeda2015CD200PB, title={[CD200 protein, bad prognostic in patients with multiple myeloma].}, author={Jorge Vela-Ojeda and M A Garc{\'i}a-Ruiz Esparza and Ysabel Padilla-Gonz{\'a}lez and F P{\'e}rez-Retiguin and E Reyes-Maldonado and Daniela Maillet and Laura Arcelia Montiel-Cervantes}, journal={Revista medica del Instituto Mexicano del Seguro Social}, year={2015}, volume={53 4}, pages={438-43} }